Physician profile
Peter A Mendel
NPI 1043219629
$1,314.02
in general payments reported to CMS, 2019-2025
15 companies · $33.75 in 2025
The $33.75 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $20.26 · 2021: $138 · 2023: $218 · 2024: $261 · 2025: $33.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $457.53 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $214.01 | 2019-2023 | Saxenda |
| Phathom Pharmaceuticals, INC. | $124.97 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $122.03 | 2024 | Arexvy |
| Merck Sharp & Dohme LLC | $119.89 | 2019-2023 | Verquvo |
| Abbvie INC. | $78.75 | 2021 | |
| Lilly USA, LLC | $36.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $30.78 | 2019 | |
| Hologic Sales and Service, LLC | $29.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.54 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.00 | 2025 | Opdualag |
| Allergan, INC. | $17.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.93 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.97 | 2019 | |
| Pfizer INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mendel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.